Zhang Kai, Miao Shipan, Yao Yitan, Yang Yating, Shi Shengya, Luo Bei, Li Mengdie, Zhang Ling, Liu Huanzhong
Department of Psychiatry, Chaohu Hospital of Anhui Medical University, Hefei, 238000, China.
Anhui Psychiatric Center, Anhui Medical University, Hefei, 238000, China.
Heliyon. 2023 Mar 9;9(3):e14199. doi: 10.1016/j.heliyon.2023.e14199. eCollection 2023 Mar.
To test the effect of prophylactic use of benzhexol in schizophrenia patients after risperidone treatment. Sixty-nine drug naïve schizophrenia patients were recruited. All patients were administered risperidone. Patients in the benzhexol group were given a benzhexol tablet of 2 mg bid daily. The controls received a placebo tablet of 2 mg bid daily. The primary outcome measured using the Extrapyramidal Symptoms Rating Scale (ESRS). The Positive and Negative Syndrome Scale (PANSS) and the Brief Psychiatric Rating Scale (BPRS) measured secondary outcome. There were significant time and group effects on the ESRS scores of the two groups. The post hoc analysis yielded significant differences at 1, 2, 4, and 8 weeks between the two groups. There was a significant time effect on the PANSS scores of the two groups. No significant group and interaction effects on the PANSS scores of the two groups. There was a significant time effect on the BPRS scores of the two groups. No serious adverse events were found in this study. Prophylactic use of benzhexol reduced extrapyramidal symptom in schizophrenia patients after risperidone treatment and did not affect the antipsychotic action of risperidone.
为测试苯海索预防性应用于利培酮治疗后的精神分裂症患者的效果。招募了69例未用过药的精神分裂症患者。所有患者均给予利培酮治疗。苯海索组患者每日两次、每次服用2mg苯海索片。对照组每日两次、每次服用2mg安慰剂片。使用锥体外系症状评定量表（ESRS）测量主要结局。使用阳性与阴性症状量表（PANSS）和简明精神病评定量表（BPRS）测量次要结局。两组的ESRS评分存在显著的时间和组间效应。事后分析显示两组在第1、2、4和8周存在显著差异。两组的PANSS评分存在显著的时间效应。两组的PANSS评分不存在显著的组间和交互效应。两组的BPRS评分存在显著的时间效应。本研究未发现严重不良事件。预防性应用苯海索可减轻利培酮治疗后精神分裂症患者的锥体外系症状，且不影响利培酮的抗精神病作用。
